iBio develops and offers product applications of its proprietary iBioLaunch and iBioModulator platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products.
The iBioLaunch platform is technology for the development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator is complementary to iBioLaunch and enables significantly improved vaccine products with higher potency and greater duration of effect.
The company announced today that the National Institute of Allergy and Infectious Diseases (part of the National Institute of Health) has awarded a contract to one of iBio’s collaborators, the Fraunhofer USA Center for Molecular Biotechnology. The contract was awarded for a new generation anthrax vaccine to be developed with the iBioLaunch platform under a research license from iBio. The first year of funding will be $1.76 million with a total contract amount of up to $9.9 million, depending on the exercise of contract options.
In October 2012, the company received a patent covering compositions of matter and methods of producing anthrax vaccines. This added to iBio’s portfolio of assets relevant to bio-defense and infectious disease product applications. Previous data published in peer-reviewed scientific journals demonstrated the effectiveness of the iBioLaunch platform for development and production of vaccine candidates for both viral and bacterial pathogens.
For additional information on iBio and its proprietary technology, visit www.ibioinc.com
Let us hear your thoughts below: